Drug Trial Radar · NCT06403501
Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
692
Planned (sponsor's estimate)
Start
May 20, 2024
Primary completion
Oct 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the safety and efficacy of clascoterone cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
ClascoteroneDrug
Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Vehicle creamDrug
Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)Time frame: Week 12
- Change From Baseline in Non-inflammatory Lesion (NIL) CountsTime frame: Week 12
- Change From Baseline in Inflammatory Lesion (IL) CountsTime frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital, Fudan University
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.